Мы используем Cookies Этот веб-сайт использует cookie-файлы, чтобы предлагать вам наиболее актуальную информацию. Просматривая этот веб-сайт, Вы принимаете cookie-файлы.
Further evaluation of galliumnitrate to attenuate progression of disease in patients with multiple myeloma is warranted.
2
Agents which have been investigated include galliumnitrate, interferon-alpha and paclitaxel both as single agents and in combination with established cytotoxic drugs.
3
These data suggest that galliumnitrate may have a positive, indirect benefit on survival in myeloma by decreasing the rate of bone resorption.
4
Galliumnitrate was shown in a small, randomized trial to attenuate the rate of bone loss in patients with myeloma treated with chemotherapy.